elagolix + estradiol + progesterone

Elagolix + estradiol + progesterone is a combination pharmaceutical product that has not been approved or marketed as a fixed-dose therapy under this specific triple combination. Elagolix is a **gonadotropin-releasing hormone (GnRH) receptor antagonist** that suppresses gonadotropin secretion, leading to reduced ovarian sex hormones (estradiol and progesterone)[2][4][5]. **Estradiol**, an estrogen, acts by binding to estrogen receptors in target tissues to mitigate bone loss that can result from hypoestrogenism due to elagolix[5][1]. **Progesterone** is a progestin that acts mainly by binding nuclear progesterone receptors to confer endometrial protection against unopposed estrogen[1][5]. Although a similar fixed-dose combination with *norethindrone* (a synthetic progestin) is used clinically (e.g., under the brand name Oriahnn for heavy menstrual bleeding associated with uterine fibroids), the precise combination of elagolix + estradiol + **progesterone** (natural hormone rather than synthetic progestin) has not been approved or is not in active clinical use according to available evidence. The principal mechanism is the suppression of ovarian function to reduce estrogen/progestin-driven pathology (primarily in gynecologic disorders).